IRIDEX (NASDAQ:IRIX) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Price Performance

IRIDEX stock opened at $1.65 on Wednesday. IRIDEX has a 52 week low of $1.27 and a 52 week high of $3.65. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. The firm’s 50-day simple moving average is $1.71 and its 200 day simple moving average is $1.76. The firm has a market capitalization of $27.37 million, a PE ratio of -2.46 and a beta of 0.84.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The firm had revenue of $11.58 million during the quarter. During the same period last year, the firm earned ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.